Press shift question mark to access a list of keyboard shortcuts
Keyboard Shortcuts
Play/PauseSPACE
Increase Volume↑
Decrease Volume↓
Seek Forward→
Seek Backward←
Captions On/Offc
Fullscreen/Exit Fullscreenf
Mute/Unmutem
Seek %0-9
Live
00:00
00:00
00:00
Chapters
Transcript
Video
Current Indications for PD-1/PD-L1 Immunotherapy in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma
Head and neck cancer and skull base surgeon Nyall London discusses three key immunotherapy clinical trials including KEYNOTE-012, Checkmate 141 and KEYNOTE-048 that have contributed to Food and Drug Administration approval for nivolumab and pembrolizumab, which are PD-1 inhibitors, for recurrent head and neck squamous cell carcinoma.
Associate Professor of Otolaryngology - Head and Neck Surgery
Dr. London was born and raised in Southern California. He received his bachelor’s degree in Microbiology from Brigham Young University followed by his M.D. Ph.D. from The University of Utah. Dr. London then completed his residency in Otolaryngology-Head ...